Previous Close | 0.1210 |
Open | 0.1256 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.1135 - 0.1258 |
52 Week Range | 0.0600 - 0.9700 |
Volume | |
Avg. Volume | 44,537 |
Market Cap | 36.07M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1370 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting psychedelics portfolio LONDON, May 25, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, provides a business update ahead of its annual financial results for the fiscal year ended Februa
Conference to take place at The National Gallery in London on May 11, 2022LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, will participate in the PSYCH Symposium: London 2022 – Shaping The Future Of Psychedelic Healthcare. Dr. Carol Routledge, Small Pharma’s Chief Medical and Scientific Officer, will join a panel dis
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4 The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Comp